The Nintendo Switch has been revealed, with more to come April 2. Here's what's confirmed and what we're still guessing at.

BACKGROUND: Hypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality and are associated with acute cardiac events in the peripartum period, as well as ...

If she goes, she risks not coming back to her family or her beloved island. Here's where Moana 2 really shows us how far Moana has grown. With age and greater status in Motunui, she's become far ...

How might Medicare price negotiations impact Novo Nordisk's battle in the marketplace with Eli Lilly? Lilly's type 2 diabetes drug Mounjaro and obesity drug Zepbound aren't eligible for Medicare ...

Luxury fashion house LVMH has reclaimed its title as Europe’s most valuable company from Novo Nordisk, as early signs of a luxury comeback coincided with fresh struggles for the Danish Ozempic ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Wegovy was approved as a 2.4mg dose by the US Food and Drug Administration (FDA) in June 2021 and in the EU in January 2022. Novo Nordisk development executive vice-president Martin Holst Lange said: ...

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...

Novo Nordisk is facing serious pressure from a ... patients taking Zepbound lost 20.2% of their weight on average, whereas patients taking Wegovy lost just 13.7% on average. Lilly's drug also ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Lone Star Funds is selecting advisers to explore a possible sale or initial public offering of Portuguese lender Novo Banco SA, according to people familiar with the matter. The private equity ...